JP2016531913A - 神経抑制性ケタミンの単層による経口投与 - Google Patents

神経抑制性ケタミンの単層による経口投与 Download PDF

Info

Publication number
JP2016531913A
JP2016531913A JP2016537782A JP2016537782A JP2016531913A JP 2016531913 A JP2016531913 A JP 2016531913A JP 2016537782 A JP2016537782 A JP 2016537782A JP 2016537782 A JP2016537782 A JP 2016537782A JP 2016531913 A JP2016531913 A JP 2016531913A
Authority
JP
Japan
Prior art keywords
ketamine
naket
tablet composition
release time
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016537782A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016531913A5 (cg-RX-API-DMAC7.html
Inventor
アレックス ニヴォロジキン，
アレックス ニヴォロジキン，
ネルソン ランドロー，
ネルソン ランドロー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amorsa Therapeutics Inc
Original Assignee
Amorsa Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amorsa Therapeutics Inc filed Critical Amorsa Therapeutics Inc
Publication of JP2016531913A publication Critical patent/JP2016531913A/ja
Publication of JP2016531913A5 publication Critical patent/JP2016531913A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2016537782A 2013-08-26 2014-08-26 神経抑制性ケタミンの単層による経口投与 Pending JP2016531913A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361869884P 2013-08-26 2013-08-26
US61/869,884 2013-08-26
US201462015513P 2014-06-22 2014-06-22
US62/015,513 2014-06-22
PCT/US2014/052786 WO2015031410A1 (en) 2013-08-26 2014-08-26 Single-layer oral dose of neuro-attenuating ketamine

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020016717A Division JP2020079273A (ja) 2013-08-26 2020-02-04 神経抑制性ケタミンの単層による経口投与

Publications (2)

Publication Number Publication Date
JP2016531913A true JP2016531913A (ja) 2016-10-13
JP2016531913A5 JP2016531913A5 (cg-RX-API-DMAC7.html) 2017-10-05

Family

ID=52587281

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016537782A Pending JP2016531913A (ja) 2013-08-26 2014-08-26 神経抑制性ケタミンの単層による経口投与
JP2020016717A Pending JP2020079273A (ja) 2013-08-26 2020-02-04 神経抑制性ケタミンの単層による経口投与

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020016717A Pending JP2020079273A (ja) 2013-08-26 2020-02-04 神経抑制性ケタミンの単層による経口投与

Country Status (5)

Country Link
US (3) US9913803B2 (cg-RX-API-DMAC7.html)
EP (2) EP3960162A1 (cg-RX-API-DMAC7.html)
JP (2) JP2016531913A (cg-RX-API-DMAC7.html)
CA (1) CA2922507C (cg-RX-API-DMAC7.html)
WO (1) WO2015031410A1 (cg-RX-API-DMAC7.html)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020536901A (ja) * 2017-10-10 2020-12-17 ダグラス・ファーマスーティカルズ・リミテッドＤｏｕｇｌａｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ． 持続放出医薬製剤及び治療方法
JP2021529732A (ja) * 2018-06-27 2021-11-04 クレキシオ バイオサイエンシーズ エルティーディー． 大うつ病性障害の処置方法
JP2022526233A (ja) * 2019-03-25 2022-05-24 ダグラス ファーマシューティカルズ エルティーディー． 持続放出性の医薬製剤
US11957645B2 (en) 2018-10-05 2024-04-16 Clexio Biosciences Ltd. Method of treating major depressive disorder
US12478592B2 (en) 2019-12-30 2025-11-25 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014240102A1 (en) 2013-03-15 2015-09-17 Janssen Pharmaceutica Nv Pharmaceutical composition of S-ketamine hydrochloride
CA2922507C (en) 2013-08-26 2022-07-05 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
US20150118300A1 (en) 2013-10-31 2015-04-30 Cima Labs Inc. Immediate Release Abuse-Deterrent Granulated Dosage Forms
PL3272338T3 (pl) * 2014-04-17 2021-01-11 Develco Pharma Schweiz Ag Doustna postać dawkowania ketaminy
US20160074340A1 (en) 2014-09-15 2016-03-17 Janssen Pharmaceutica Nv VAL66MET (SNP rs6265) GENOTYPE SPECIFIC DOSING REGIMENS AND METHODS FOR THE TREATMENT OF DEPRESSION
EP3215147B1 (en) 2014-11-04 2024-02-28 ACADIA Pharmaceuticals Inc. Neuro-attenuating norketamine compounds and methods
WO2016094358A1 (en) * 2014-12-08 2016-06-16 Cima Labs Inc. Immediate release abuse-deterrent granulated dosage forms
AU2016288188B2 (en) 2015-06-27 2021-08-05 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
MX2019012285A (es) * 2017-04-13 2020-11-06 Ovid Therapeutics Inc Metodos de tratamiento de encefalopatias del desarrollo.
EP3641742A2 (en) * 2017-06-23 2020-04-29 Develco Pharma Schweiz AG Hydroxynorketamine for the use in the treatment of depression
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
US10869838B2 (en) 2017-10-10 2020-12-22 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US12090123B2 (en) 2017-10-10 2024-09-17 Douglas Pharmaceuticals Ltd. Extended release pharmaceutical formulation
US10441544B2 (en) 2017-10-10 2019-10-15 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation
US11471415B2 (en) 2017-10-10 2022-10-18 Douglas Pharmaceuticals, Ltd. Extended release pharmaceutical formulation and methods of treatment
JOP20200156A1 (ar) 2017-12-22 2022-10-30 Janssen Pharmaceuticals Inc إيسكيتامين لعلاج الاكتئاب
ES2907692T3 (es) 2017-12-29 2022-04-26 Celon Pharma Sa Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento
WO2020075134A1 (en) 2018-10-11 2020-04-16 Clexio Biosciences Ltd. Esketamine for use in treating major depressive disorder
CN114126595A (zh) 2019-03-05 2022-03-01 杨森制药公司 用于治疗抑郁症的艾司氯胺酮
US20220062200A1 (en) 2019-05-07 2022-03-03 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
WO2020225773A1 (en) 2019-05-07 2020-11-12 Clexio Biosciences Ltd. Abuse-deterrent dosage forms containing esketamine
CA3155176A1 (en) 2019-10-11 2021-04-15 Pike Therapeutics, Inc., 1219014 B.C. Ltd. Transdermal compositions comprising cannabidiol (cbd) for use in the treatment of seizure disorders
WO2021137147A1 (en) 2019-12-30 2021-07-08 Clexio Biosciences Ltd. Dosage regime with esketamine for treating major depressive disorder

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204116A (en) * 1991-05-01 1993-04-20 Alza Corporation Dosage form providing immediate therapy followed by prolonged therapy
US6194000B1 (en) * 1995-10-19 2001-02-27 F.H. Faulding & Co., Limited Analgesic immediate and controlled release pharmaceutical composition
JP2004520410A (ja) * 2001-02-27 2004-07-08 セフアロン・インコーポレーテツド 経口可溶性投与剤形のための組成物および製造方法
JP2004528338A (ja) * 2001-05-02 2004-09-16 ユーロ−セルティーク，エス．エイ． 一日に一回のオキシコドン製剤
US6855735B2 (en) * 2002-03-20 2005-02-15 Temple University Of The Commonwealth System Of Higher Education Ketamine treatment of restless legs syndrome
WO2013003669A2 (en) * 2011-06-30 2013-01-03 University Of South Florida Compositions, methods of use, and methods of treatment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1103256A1 (de) * 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
TW200407108A (en) * 2002-06-10 2004-05-16 Wyeth Corp Novel formate salt of O-desmethyl-venlafaxine
US20080027119A1 (en) * 2002-07-31 2008-01-31 Lippa Arnold S Methods and compositions employing bicifadine for the treatment of acute pain, chronic pain, and symptoms of neuropathic disorders
WO2006053012A2 (en) * 2004-11-10 2006-05-18 Trinity Laboratories, Inc. Novel pharmaceutical compositions for treating acquired chronic pain and associated dysphoria
WO2008118785A2 (en) * 2007-03-23 2008-10-02 Tikvah Therapeutics Methods for treating depression using immediate-impact treatments and d-cycloserine
AU2008245662A1 (en) 2007-04-26 2008-11-06 Auspex Pharmaceuticals, Inc. Deuterium labelled ketamine
WO2009131794A1 (en) * 2008-03-27 2009-10-29 University Of Kentucky Research Foundation Opioid-ketamine and norketamine codrug combinations for pain management
WO2014020155A1 (en) * 2012-08-02 2014-02-06 Clinpharm Reform Gmbh Oral transmucosal adminstration forms of s-ketamine
CA2922507C (en) 2013-08-26 2022-07-05 Amorsa Therapeutics, Inc. Single-layer oral dose of neuro-attenuating ketamine
CN105580178B (zh) 2013-09-23 2018-01-05 康维恩公司 用于高温电池系统的再循环设备及方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204116A (en) * 1991-05-01 1993-04-20 Alza Corporation Dosage form providing immediate therapy followed by prolonged therapy
US6194000B1 (en) * 1995-10-19 2001-02-27 F.H. Faulding & Co., Limited Analgesic immediate and controlled release pharmaceutical composition
JP2004520410A (ja) * 2001-02-27 2004-07-08 セフアロン・インコーポレーテツド 経口可溶性投与剤形のための組成物および製造方法
JP2004528338A (ja) * 2001-05-02 2004-09-16 ユーロ−セルティーク，エス．エイ． 一日に一回のオキシコドン製剤
US6855735B2 (en) * 2002-03-20 2005-02-15 Temple University Of The Commonwealth System Of Higher Education Ketamine treatment of restless legs syndrome
WO2013003669A2 (en) * 2011-06-30 2013-01-03 University Of South Florida Compositions, methods of use, and methods of treatment

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CLINICAL DRUG INVESTIGATION, vol. 29, no. 5, JPN6018017739, 2009, pages 317 - 324, ISSN: 0004128347 *
DRUG AND ALCOHOL DEPENDENCE, vol. 83, JPN6018017735, 2006, pages 247 - 254, ISSN: 0004128346 *
J. FORENSIC SCI., vol. 48, no. 6, JPN6018017737, November 2003 (2003-11-01), pages 1 - 11, ISSN: 0003934127 *
医療薬学, vol. 32, no. 4, JPN6018017733, 2006, pages 275 - 288, ISSN: 0004128345 *
薬学雑誌, vol. 119, no. 6, JPN6018017731, 1999, pages 980 - 987, ISSN: 0004128344 *

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020536901A (ja) * 2017-10-10 2020-12-17 ダグラス・ファーマスーティカルズ・リミテッドＤｏｕｇｌａｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ． 持続放出医薬製剤及び治療方法
JP7364558B2 (ja) 2017-10-10 2023-10-18 ダグラス ファーマシューティカルズ エルティーディー． 持続放出医薬製剤及び治療方法
JP2021529732A (ja) * 2018-06-27 2021-11-04 クレキシオ バイオサイエンシーズ エルティーディー． 大うつ病性障害の処置方法
US12036189B2 (en) 2018-06-27 2024-07-16 Clexio Biosciences Ltd. Method of treating major depressive disorder
US11957645B2 (en) 2018-10-05 2024-04-16 Clexio Biosciences Ltd. Method of treating major depressive disorder
JP2022526233A (ja) * 2019-03-25 2022-05-24 ダグラス ファーマシューティカルズ エルティーディー． 持続放出性の医薬製剤
JP7381597B2 (ja) 2019-03-25 2023-11-15 ダグラス ファーマシューティカルズ エルティーディー． 持続放出性の医薬製剤
US12478592B2 (en) 2019-12-30 2025-11-25 Clexio Biosciences Ltd. Dosage regime with esketamine for treating neuropsychiatric or neurological conditions

Also Published As

Publication number Publication date
US10653629B2 (en) 2020-05-19
EP3035918B1 (en) 2021-06-30
WO2015031410A1 (en) 2015-03-05
US11554100B2 (en) 2023-01-17
CA2922507C (en) 2022-07-05
US9913803B2 (en) 2018-03-13
EP3960162A1 (en) 2022-03-02
US20160199304A1 (en) 2016-07-14
EP3035918A1 (en) 2016-06-29
JP2020079273A (ja) 2020-05-28
US20180153813A1 (en) 2018-06-07
CA2922507A1 (en) 2015-03-05
EP3035918A4 (en) 2017-03-29
US20200261370A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
JP2020079273A (ja) 神経抑制性ケタミンの単層による経口投与
AU657027B2 (en) Controlled release oxycodone compositions
KR101784777B1 (ko) 타펜타돌 조성물
US10300141B2 (en) Tamper resistant dosage form comprising inorganic salt
US8758815B2 (en) Pharmaceutical compositions comprising a combination of metformin and sitagliptin
MXPA00012957A (es) Composicion para dosis oral de liberacion extendida.
KR20100129776A (ko) 왁스를 포함하는 서방형 제형
JP2005506367A (ja) 有効物質を徐放する３−（３−ジメチルアミノ−１−エチル−２−メチル−プロピル）フェノール含有医薬
JP6444996B2 (ja) 調節放出製剤
CN104812378A (zh) 固体剂型
KR20130030261A (ko) 활성제-무함유 과립 및 그를 포함하는 정제의 제조
KR20180016651A (ko) 통증 및 오피오이드 장 기능장애 증후군의 치료를 위한 히드로모르폰 및 날록손
KR20060108675A (ko) 서방성 약학 제형
WO2003082261A1 (en) Extended release venlafaxine formulations
KR20080013927A (ko) 벤라팍스의 하나 이상 형태의 개질 방출 조성물
WO1999002142A2 (en) Novel composition comprising an ssri and a beta-blocker
EP2269586A1 (en) Pharmaceutical composition comprising desloratadine
EP2848260B1 (en) Novel formulations of thiocolchicoside
KR20190075718A (ko) 용출율이 개선된 트라마돌 또는 이의 약학적으로 허용가능한 염 및 프레가발린 또는 이의 약학적으로 허용가능한 염을 포함하는 다층 제제
US20230028539A1 (en) Pharmaceutical composition, complementary kit and application thereof
KR101515222B1 (ko) 티아넵틴 나트륨 함유 제어방출성 경구용 단층 제제 및 이의 제조방법
KR20100102441A (ko) 제어방출형 고혈압 치료제의 조성물 및 그 제조방법

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170828

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170828

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180815

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190219

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191004